Novo Nordisk shares fall on weight-loss drug trial

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial.  Novo's results from its Redefine 2 late-stage trial of CagriSema showed that patients on the highest dose of the drug lost 15.7% of their weight. Patients who were placed on the placebo lost 3.1%, according to the data. The trial included 1,206 people with obesity or who were overweight and had type 2 diabetes. They had a mean baseline body weight of about 224 pounds. Shares of ...